Jonathan P Chang

US Patent:

50339656, Jul 23, 1991

Filed:

Oct 19, 1989

Appl. No.:

7/424188

Inventors:

Sam Chiu - Brooklyn NY
Jonathan Chang - Alta Loma CA

International Classification:

G09B 2700

US Classification:

434131

Abstract:

A three dimensional globe utilizing a transparent spherical globe having geographical areas outlined thereon with fluorescent paint combined with an external black light to illuminate and render uniquely observable all of the outline of the geographical areas. A clock with spherical members mounted at the ends of the hands thereon are associated with the globe to simulate the movement of planets in relation to the globe with the balls being relatively small and also fluorescent colored for effective illumination by the black light. The globe provides a unique, attractive and informative globe utilizing high technology and effective structure for movement of the globe in a rotational manner about a substantially vertical axis.

US Patent:

20230109065, Apr 6, 2023

Filed:

Sep 28, 2022

Appl. No.:

17/935957

Inventors:

- New York NY, US
Dennis VITKUP - New York NY, US
Jonathan CHANG - Los Altos CA, US
Jiayao WANG - New York NY, US

International Classification:

C12Q 1/6883

Abstract:

It was discovered that, for individuals with certain types of mutations, clinical outcomes or phenotypes can be very accurately predicted. For example, for an individual with autism harboring a de novo LGD mutation, the patient’s IQ, behavioral phenotypes, and motor/movement phenotypes, and the severity of autism can be predicted. For these LGD mutations, due to a mRNA surveillance mechanism called NMD (nonsense-mediated decay), it was discovered that clinical outcomes and phenotypes are strongly correlated with the expression intensity of the exon harboring the mutation. A method/model was developed, which is called PDS (phenotype dosage sensitivity), to predict phenotypes based on this observation, and the model is able to predict phenotypes at a much higher level of accuracy not previously possible. This disclosure is the first to link LGD mutations and clinical phenotypes in this manner.